COMPARISON 1. ARIPIPRAZOLE vs OLANZAPINE: Global state: No clinically important response (as defined by the original studies)
It is very uncertain whether COMPARISON 5. ARIPIPRAZOLE changes global state: No clinically significant response compared with OLANZAPINE (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
COMPARISON 5. ARIPIPRAZOLE vs OLANZAPINE Global state: No clinically significant response · patients with schizophrenia It is very uncertain whether COMPARISON 5. ARIPIPRAZOLE changes global state: No clinically significant response compared with OLANZAPINE (very low certainty). Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane Headline outcomes only | RR 1.06 [0.96, 1.17] | 11 studies · 1739 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.